Clinical use of exhaled volatile organic compounds in pulmonary diseases: a systematic review

Respiratory Research

Edward Dompeling²  Onno CP van Schayck¹  Quirijn Jöbsis²  Linda JTM van der Sande²  Kim DG van de Kant² 

[1] Department of General Practice, CAPHRI, MUMC, P.O. Box 5800, 6202, AZ, Maastricht, the Netherlands;Department of Pediatric Pulmonology, School for Public Health and Primary Care (CAPHRI), Maastricht University Medical Center (MUMC), P.O. Box 5800, 6202, AZ, Maastricht, the Netherlands

关键词: Biomarkers;    Airway inflammation;    Cystic fibrosis;    Lung cancer;    COPD;    Asthma;    VOCs;   

Others  :  796572
DOI  :  10.1186/1465-9921-13-117

 received in 2012-09-10, accepted in 2012-12-05,  发布年份 2012

【 摘 要 】

There is an increasing interest in the potential of exhaled biomarkers, such as volatile organic compounds (VOCs), to improve accurate diagnoses and management decisions in pulmonary diseases. The objective of this manuscript is to systematically review the current knowledge on exhaled VOCs with respect to their potential clinical use in asthma, lung cancer, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and respiratory tract infections. A systematic literature search was performed in PubMed, EMBASE, Cochrane database, and reference lists of retrieved studies. Controlled, clinical, English-language studies exploring the diagnostic and monitoring value of VOCs in asthma, COPD, CF, lung cancer and respiratory tract infections were included. Data on study design, setting, participant characteristics, VOCs techniques, and outcome measures were extracted. Seventy-three studies were included, counting in total 3,952 patients and 2,973 healthy controls. The collection and analysis of exhaled VOCs is non-invasive and could be easily applied in the broad range of patients, including subjects with severe disease and children. Various research groups demonstrated that VOCs profiles could accurately distinguish patients with a pulmonary disease from healthy controls. Pulmonary diseases seem to be characterized by a disease specific breath-print, as distinct profiles were found in patients with dissimilar diseases. The heterogeneity of studies challenged the inter-laboratory comparability. In conclusion, profiles of VOCs are potentially able to accurately diagnose various pulmonary diseases. Despite these promising findings, multiple challenges such as further standardization and validation of the diverse techniques need to be mastered before VOCs can be applied into clinical practice.

【 授权许可】

   
2012 van de Kant et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176(6):532-555.
• [2]Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, et al.: Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J 2008, 31(1):143-178.
• [3]Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249.
• [4]Scott M, Raza A, Karmaus W, Mitchell F, Grundy J, Kurukulaaratchy RJ, Arshad SH, Roberts G: Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax 2010, 65(3):258-262.
• [5]Miekisch W, Schubert JK, Noeldge-Schomburg GF: Diagnostic potential of breath analysis–focus on volatile organic compounds. Clin Chim Acta 2004, 347(1–2):25-39.
• [6]Buszewski B, Kesy M, Ligor T, Amann A: Human exhaled air analytics: biomarkers of diseases. Biomed Chromatogr 2007, 21(6):553-566.
• [7]Phillips M, Cataneo RN, Cummin AR, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WN: Detection of lung cancer with volatile markers in the breath. Chest 2003, 123(6):2115-2123.
• [8]Ras MR, Borrull F, Marce RM: Sampling and preconcentration techniques for determination of volatile organic compounds in air samples. TrAC 2009, 28(3):347-361.
• [9]Pavlou AKTAPF: Sniffing out the truth: Clinical diagnosis using the electronic nose. Clin Chem Lab Med 2000, 38(2):99-112.
• [10]Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, Resta O, Willard NP, Vink TJ, Rabe KF, et al.: An electronic nose in the discrimination of patients with asthma and controls. J Allergy Clin Immunol 2007, 120(4):856-862.
• [11]Di Natale C, Macagnano A, Martinelli E, Paolesse R, D'Arcangelo G, Roscioni C, Finazzi-Agro A, D'Amico A: Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors. Biosens Bioelectron 2003, 18(10):1209-1218.
• [12]Dragonieri S, Annema JT, Schot R, van der Schee MP, Spanevello A, Carratu P, Resta O, Rabe KF, Sterk PJ: An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung Cancer 2009, 64(2):166-170.
• [13]Machado RF, Laskowski D, Deffenderfer O, Burch T, Zheng S, Mazzone PJ, Mekhail T, Jennings C, Stoller JK, Pyle J, et al.: Detection of lung cancer by sensor array analyses of exhaled breath. Am J Respir Crit Care Med 2005, 171(11):1286-1291.
• [14]Robroeks CM, van Berkel JJ, Dallinga JW, Jöbsis Q, Zimmermann LJ, Hendriks HJ, Wouters MF, van der Grinten CP, van de Kant KD, van Schooten FJ, et al.: Metabolomics Of Volatile Organic Compounds In Cystic Fibrosis Patients and Controls. Pediatr Res 2010, 68(1):75-80.
• [15]Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ: Exhaled Breath Profiling Enables Discrimination of Chronic Obstructive Pulmonary Disease and Asthma. Am J Respir Crit Care Med 2009, 180:1076-1082.
• [16]Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009, 62(10):1006-1012.
• [17]Caldeira M, Barros AS, Bilelo MJ, Parada A, Camara JS, Rocha SM: Profiling allergic asthma volatile metabolic patterns using a headspace-solid phase microextraction/gas chromatography based methodology. J Chromatogr A 2011, 1218(24):3771-3780.
• [18]Caldeira M, Perestrelo R, Barros AS, Bilelo MJ, Morete A, Camara JS, Rocha SM: Allergic asthma exhaled breath metabolome: A challenge for comprehensive two-dimensional gas chromatography. J Chromatogr A 2012, 1254:87-97.
• [19]Dallinga JW, Robroeks CM, van Berkel JJ, Moonen EJ, Godschalk RW, Jöbsis Q, Dompeling E, Wouters EF, van Schooten FJ: Volatile organic compounds in exhaled breath as a diagnostic tool for asthma in children. Clin Exp Allergy 2010, 40(1):68-76.
• [20]Ibrahim B, Basanta M, Cadden P, Singh D, Douce D, Woodcock A, Fowler SJ: Non-invasive phenotyping using exhaled volatile organic compounds in asthma. Thorax 2011, 66(9):804-809.
• [21]Larstad MA, Toren K, Bake B, Olin AC: Determination of ethane, pentane and isoprene in exhaled air–effects of breath-holding, flow rate and purified air. Acta Physiol (Oxf) 2007, 189(1):87-98.
• [22]Montuschi P, Santonico M, Mondino C, Pennazza G, Mantini G, Martinelli E, Capuano R, Ciabattoni G, Paolesse R, Di Natale C, et al.: Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest 2010, 137(4):790-796.
• [23]Olopade CO, Zakkar M, Swedler WI, Rubinstein I: Exhaled pentane levels in acute asthma. Chest 1997, 111(4):862-865.
• [24]Paredi P, Kharitonov SA, Barnes PJ: Elevation of exhaled ethane concentration in asthma. Am J Respir Crit Care Med 2000, 162:1450-1454.
• [25]Basanta M, Jarvis RM, Xu Y, Blackburn G, Tal-Singer R, Woodcock A, Singh D, Goodacre R, Thomas CL, Fowler SJ: Non-invasive metabolomic analysis of breath using differential mobility spectrometry in patients with chronic obstructive pulmonary disease and healthy smokers. Analyst 2010, 135(2):315-320.
• [26]Cristescu SM, Gietema HA, Blanchet L, Kruitwagen CL, Munnik P, van Klaveren RJ, Lammers JW, Buydens L, Harren FJ, Zanen P: Screening for emphysema via exhaled volatile organic compounds. J Breath Res 2011, 5(4):046009.
• [27]Fens N, Roldaan AC, van der Schee MP, Boksem RJ, Zwinderman AH, Bel EH, Sterk PJ: External validation of exhaled breath profiling using an electronic nose in the discrimination of asthma with fixed airways obstruction and chronic obstructive pulmonary disease. Clin Exp Allergy 2011, 41(10):1371-1378.
• [28]Hattesohl AD, Jorres RA, Dressel H, Schmid S, Vogelmeier C, Greulich T, Noeske S, Bals R, Koczulla AR: Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirology 2011, 16(8):1258-1264.
• [29]Hauschild AC, Baumbach JI, Baumbach J: Integrated statistical learning of metabolic ion mobility spectrometry profiles for pulmonary disease identification. Genet Mol Res 2012., 11(AOP)
• [30]Paredi P, Kharitonov SA, Leak D, Ward S, Cramer D, Barnes PJ: Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 162(2 Pt 1):369-373.
• [31]Phillips CO, Syed Y, Parthalain NM, Zwiggelaar R, Claypole TC, Lewis KE: Machine learning methods on exhaled volatile organic compounds for distinguishing COPD patients from healthy controls. J Breath Res 2012, 6(3):036003.
• [32]Timms C, Thomas PS, Yates DH: Detection of gastro-oesophageal reflux disease (GORD) in patients with obstructive lung disease using exhaled breath profiling. J Breath Res 2012, 6(1):016003.
• [33]van Berkel JJ, Dallinga JW, Moller GM, Godschalk RW, Moonen EJ, Wouters EF, van Schooten FJ: A profile of volatile organic compounds in breath discriminates COPD patients from controls. Respir Med 2010, 104(4):557-563.
• [34]Barker M, Hengst M, Schmid J, Buers HJ, Mittermaier B, Klemp D, Koppmann R: Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis. Eur Respir J 2006, 27(5):929-936.
• [35]Enderby B, Smith D, Carroll W, Lenney W: Hydrogen cyanide as a biomarker for Pseudomonas aeruginosa in the breath of children with cystic fibrosis. Pediatr Pulmonol 2009, 44(2):142-147.
• [36]Gilchrist FJ, Razavi C, Webb AK, Jones AM, Spanel P, Smith D, Lenney W: An investigation of suitable bag materials for the collection and storage of breath samples containing hydrogen cyanide. J Breath Res 2012, 6(3):036004.
• [37]Kamboures MA, Blake DR, Cooper DM, Newcomb RL, Barker M, Larson JK, Meinardi S, Nussbaum E, Rowland FS: Breath sulfides and pulmonary function in cystic fibrosis. Proc Natl Acad Sci USA 2005, 102(44):15762-15767.
• [38]McGrath LT, Patrick R, Mallon P, Dowey L, Silke B, Norwood W, Elborn S: Breath isoprene during acute respiratory exacerbation in cystic fibrosis. Eur Respir J 2000, 16(6):1065-1069.
• [39]Paredi P, Kharitonov SA, Leak D, Shah PL, Cramer D, Hodson ME, Barnes PJ: Exhaled ethane is elevated in cystic fibrosis and correlates with carbon monoxide levels and airway obstruction. Am J Respir Crit Care Med 2000, 161(4 Pt 1):1247-1251.
• [40]Shestivska V, Nemec A, Drevinek P, Sovova K, Dryahina K, Spanel P: Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometry. Rapid Commun Mass Spectrom 2011, 25(17):2459-2467.
• [41]Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M, Ligor T, Filipiak W, Denz H, Fiegl M, et al.: Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer 2009, 9:348. BioMed Central Full Text
• [42]Buszewski B, Ligor T, Jezierski T, Wenda-Piesik A, Walczak M, Rudnicka J: Identification of volatile lung cancer markers by gas chromatography–mass spectrometry: comparison with discrimination by canines. Anal Bioanal Chem 2012, 404(1):141-146.
• [43]Crohns M, Saarelainen S, Laitinen J, Peltonen K, Alho H, Kellokumpu-Lehtinen P: Exhaled pentane as a possible marker for survival and lipid peroxidation during radiotherapy for lung cancer–a pilot study. Free Radic Res 2009, 43(10):965-974.
• [44]D'Amico A, Pennazza G, Santonico M, Martinelli E, Roscioni C, Galluccio G, Paolesse R, Di Natale C: An investigation on electronic nose diagnosis of lung cancer. Lung Cancer 2010, 68(2):170-176.
• [45]Fuchs P, Loeseken C, Schubert JK, Miekisch W: Breath gas aldehydes as biomarkers of lung cancer. Int J Cancer 2010, 126(11):2663-2670.
• [46]Gaspar EM, Lucena AF, Duro da Costa J, Chaves das Neves H: Organic metabolites in exhaled human breath–a multivariate approach for identification of biomarkers in lung disorders. J Chromatogr A 2009, 1216(14):2749-2756.
• [47]Gordon SM, Szidon JP, Krotoszynski BK, Gibbons RD, O'Neill HJ: Volatile organic compounds in exhaled air from patients with lung cancer. Clin Chem 1985, 31(8):1278-1282.
• [48]Kischkel S, Miekisch W, Sawacki A, Straker EM, Trefz P, Amann A, Schubert JK: Breath biomarkers for lung cancer detection and assessment of smoking related effects–confounding variables, influence of normalization and statistical algorithms. Clin Chim Acta 2010, 411(21–22):1637-1644.
• [49]Ligor M, Ligor T, Bajtarevic A, Ager C, Pienz M, Klieber M, Denz H, Fiegl M, Hilbe W, Weiss W, et al.: Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry. Clin Chem Lab Med 2009, 47(5):550-560.
• [50]Mazzone PJ, Hammel J, Dweik R, Na J, Czich C, Laskowski D, Mekhail T: Diagnosis of lung cancer by the analysis of exhaled breath with a colorimetric sensor array. Thorax 2007, 62(7):565-568.
• [51]Mazzone PJ, Wang XF, Xu Y, Mekhail T, Beukemann MC, Na J, Kemling JW, Suslick KS, Sasidhar M: Exhaled breath analysis with a colorimetric sensor array for the identification and characterization of lung cancer. J Thorac Oncol 2012, 7(1):137-142.
• [52]Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Haick H: Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol 2009, 4(10):669-673.
• [53]Peng G, Hakim M, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, Tisch U, Haick H: Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. BJC 2010, 103:542-551.
• [54]Phillips M, Gleeson K, Hughes JM, Greenberg J, Cataneo RN, Baker L, McVay WP: Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Lancet 1999, 353(9168):1930-1933.
• [55]Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Greenberg J, Kloss R, Maxfield RA, Munawar MI, Pass HI, et al.: Prediction of lung cancer using volatile biomarkers in breath. Cancer Biomark 2007, 3(2):95-109.
• [56]Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, et al.: Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta 2008, 393(2):76-84.
• [57]Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A: Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res 2005, 6:71. BioMed Central Full Text
• [58]Poli D, Goldoni M, Caglieri A, Ceresa G, Acampa O, Carbognani P, Rusca M, Corradi M: Breath analysis in non small cell lung cancer patients after surgical tumour resection. Acta Biomed 2008, 79(Suppl 1):64-72.
• [59]Poli D, Goldoni M, Corradi M, Acampa O, Carbognani P, Internullo E, Casalini A, Mutti A: Determination of aldehydes in exhaled breath of patients with lung cancer by means of on-fiber-derivatisation SPME-GC/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2010, 878(27):2643-2651.
• [60]Preti G, Labows JN, Kostelc JG, Aldinger S, Daniele R: Analysis of lung air from patients with bronchogenic carcinoma and controls using gas chromatography–mass spectrometry. J Chromatogr 1988, 432:1-11.
• [61]Rudnicka J, Kowalkowski T, Ligor T, Buszewski B: Determination of volatile organic compounds as biomarkers of lung cancer by SPME-GC-TOF/MS and chemometrics. J Chromatogr B Analyt Technol Biomed Life Sci 2011, 879(30):3360-3366.
• [62]Skeldon KD, McMillan LC, Wyse CA, Monk SD, Gibson G, Patterson C, France T, Longbottom C, Padgett MJ: Application of laser spectroscopy for measurement of exhaled ethane in patients with lung cancer. Respir Med 2006, 100(2):300-306.
• [63]Song G, Qin T, Liu H, Xu GB, Pan YY, Xiong FX, Gu KS, Sun GP, Chen ZD: Quantitative breath analysis of volatile organic compounds of lung cancer patients. Lung Cancer 2010, 67(2):227-231.
• [64]Steeghs MM, Cristescu SM, Munnik P, Zanen P, Harren FJ: An off-line breath sampling and analysis method suitable for large screening studies. Physiol Meas 2007, 28(5):503-514.
• [65]Ulanowska A, Kowalkowski T, Trawinska E, Buszewski B: The application of statistical methods using VOCs to identify patients with lung cancer. J Breath Res 2011, 5(4):046008.
• [66]Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl GA, Amann A: Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas. Int J Mass Spectrom 2007, 265:49-59.
• [67]Westhoff M, Litterst P, Freitag L, Urfer W, Bader S, Baumbach JI: Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study. Thorax 2009, 64(9):744-748.
• [68]Chapman EA, Thomas PS, Stone E, Lewis C, Yates DH: A breath test for malignant mesothelioma using an electronic nose. Eur Respir J 2012, 40(2):448-454.
• [69]Dragonieri S, van der Schee MP, Massaro T, Schiavulli N, Brinkman P, Pinca A, Carratu P, Spanevello A, Resta O, Musti M, et al.: An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls. Lung Cancer 2012, 75(3):326-331.
• [70]de Gennaro G, Dragonieri S, Longobardi F, Musti M, Stallone G, Trizio L, Tutino M: Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure. Anal Bioanal Chem 2010, 398(7–8):3043-3050.
• [71]Chambers ST, Syhre M, Murdoch DR, McCartin F, Epton MJ: Detection of 2-pentylfuran in the breath of patients with Aspergillus fumigatus. Med Mycol 2009, 47(5):468-476.
• [72]Hanson CW 3rd, Thaler ER: Electronic nose prediction of a clinical pneumonia score: biosensors and microbes. Anesthesiology 2005, 102(1):63-68.
• [73]Hockstein NG, Thaler ER, Torigian D, Miller WT Jr, Deffenderfer O, Hanson CW: Diagnosis of pneumonia with an electronic nose: correlation of vapor signature with chest computed tomography scan findings. Laryngoscope 2004, 114(10):1701-1705.
• [74]Hockstein NG, Thaler ER, Lin Y, Lee DD, Hanson CW: Correlation of pneumonia score with electronic nose signature: A prospective study. Ann Otol Rhinol Laryngol 2005, 114(7):504-508.
• [75]Kanoh S, Kobayashi H, Motoyoshi K: Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest 2005, 128(4):2387-2392.
• [76]Kolk AH, van Berkel JJ, Claassens MM, Walters E, Kuijper S, Dallinga JW, van Schooten FJ: Breath analysis as a potential diagnostic tool for tuberculosis. Int J Tuberc Lung Dis 2012, 16(6):777-782.
• [77]Phillips M, Cataneo RN, Condos R, Ring Erickson GA, Greenberg J, La Bombardi V, Munawar MI, Tietje O: Volatile biomarkers of pulmonary tuberculosis in the breath. Tuberculosis 2007, 87(1):44-52.
• [78]Phillips M, Basa-Dalay V, Bothamley G, Cataneo RN, Lam PK, Natividad MP, Schmitt P, Wai J: Breath biomarkers of active pulmonary tuberculosis. Tuberculosis 2010, 90(2):145-151.
• [79]Phillips M, Basa-Dalay V, Blais J, Bothamley G, Chaturvedi A, Modi KD, Pandya M, Natividad MP, Patel U, Ramraje NN, et al.: Point-of-care breath test for biomarkers of active pulmonary tuberculosis. Tuberculosis 2012, 92(4):314-320.
• [80]Syhre M, Manning L, Phuanukoonnon S, Harino P, Chambers ST: The scent of Mycobacterium tuberculosis–part II breath. Tuberculosis 2009, 89(4):263-266.
• [81]Scholpp J, Schubert JK, Miekisch W, Geiger K: Breath markers and soluble lipid peroxidation markers in critically ill patients. Clin Chem Lab Med 2002, 40(6):587-594.
• [82]Schubert JK, Muller WP, Benzing A, Geiger K: Application of a new method for analysis of exhaled gas in critically ill patients. Intensive Care Med 1998, 24(5):415-421.
• [83]Fens N, de Nijs SB, Peters S, Dekker T, Knobel HH, Vink TJ, Willard NP, Zwinderman AH, Krouwels FH, Janssen HG, et al.: Exhaled air molecular profiling in relation to inflammatory subtype and activity in COPD. Eur Respir J 2011, 38(6):1301-1309.
• [84]Fuchs D, Jamnig H, Heininger P, Klieber M, Schroecksnadel S, Fiegl M, Hackl M, Denz H, Amann A: Decline of exhaled isoprene in lung cancer patients correlates with immune activation. J Breath Res 2012, 6(2):027101.
• [85]Filipiak W, Ruzsanyi V, Mochalski P, Filipiak A, Bajtarevic A, Ager C, Denz H, Hilbe W, Jamnig H, Hackl M, et al.: Dependence of exhaled breath composition on exogenous factors, smoking habits and exposure to air pollutants. J Breath Res 2012, 6(3):036008.
• [86]Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, et al.: Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005, 26(3):523-548.